Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Affibody AB and GE Healthcare in Molecular Collaboration

By MedImaging staff writers
Posted on 28 Jun 2006
Affibody AB (Stockholm, Sweden) has entered a research agreement with GE Healthcare (Chalfont Sr. Giles, UK), a division of the General Electric Co.. Under the agreement, Affibody will provide Affibody molecules for three disease targets as defined by GE Healthcare.

Affibody molecules, with their favorable biodistribution, high target specificity, and acceptability to protein-engineering approaches, are considered suitable candidates for targeted in vivo imaging applications. The goal is to allow early diagnosis of disease and thereby allowing clinicians to optimize the therapy on a customized basis. Under the agreement, GE Healthcare has the exclusive option to take any licenses required for developing and marketing imaging agents resulting from this collaboration. Affibody retains all rights for use of the selected Affibody molecules outside the scope of in vivo diagnostic and medical imaging.

Dr. Ulf Boberg, chief executive officer, Affibody, commented, "We are delighted to announce an agreement with GE Healthcare, regarded as a leader in the rapidly expanding field of molecular imaging. This agreement broadens the current uses of Affibody molecules in medicine, and demonstrates the increasing interest in the use of molecular imaging agents to monitor disease.”

Affibody uses innovative protein engineering technologies for the development of the affinity ligand, Affibody molecules. These small, robust protein molecules can be designed to bind to a number of target proteins, are easily produced, and have a high stability in a broad range of conditions. They appear well-suited for molecular imaging, and when combined with a cytotoxic payload, could potentially be utilized for targeted therapy.

Affibody also develops Affibody molecules for various biotechnology applications in a number of commercial collaborations. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute (Stockholm, Sweden).



Related Links:
Affibody
GE Healthcare
High-Precision QA Tool
DEXA Phantom
New
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
New
Mammo DR Retrofit Solution
DR Retrofit Mammography
Portable X-ray Unit
AJEX140H

Channels

Nuclear Medicine

view channel
Image: Perovskite crystal boules are grown in carefully controlled conditions from the melt (Photo courtesy of Mercouri Kanatzidis/Northwestern University)

New Camera Sees Inside Human Body for Enhanced Scanning and Diagnosis

Nuclear medicine scans like single-photon emission computed tomography (SPECT) allow doctors to observe heart function, track blood flow, and detect hidden diseases. However, current detectors are either... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.